Loading...
XPAR
BOI
Market cap356mUSD
Oct 09, Last price  
17.60EUR
1D
-0.56%
1Q
-36.00%
Jan 2017
-79.09%
Name

Boiron SA

Chart & performance

D1W1MN
XPAR:BOI chart
P/E
9.36
P/S
0.61
EPS
1.88
Div yield, %
6.56%
Shrs. gr., 5y
0.04%
Rev. gr., 5y
-0.49%
Revenues
501m
+2.78%
398,674,000434,471,000466,894,000526,279,000520,600,000523,452,000566,294,000617,988,000609,984,000607,962,000614,491,000617,542,000604,216,000557,123,000513,582,000455,201,000534,239,000493,248,000487,559,000501,106,000
Net income
33m
+187.96%
10,245,00027,157,00039,184,00059,889,00043,283,00042,264,00049,626,00082,396,00089,049,00073,932,00077,725,00078,243,00057,459,00040,630,00026,209,00028,556,00044,673,00035,827,00011,336,00032,643,000
CFO
53m
+34.67%
38,569,00056,130,00065,479,00080,202,00051,638,00058,821,00088,594,000107,017,00096,156,000103,164,000110,131,000104,745,00084,250,00051,555,00068,268,00033,317,00058,690,00045,491,00039,533,00053,240,000
Dividend
Jun 03, 20261.35 EUR/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Boiron S.A., founded in Messimy, France, in 1932, is a pharmaceutical company dedicated to the production and global sale of homeopathic medicines. Its market presence spans France, the broader European continent, North America, and numerous international territories. The company's offerings range from non-proprietary and proprietary formulations to a variety of branded homeopathic treatments. Among its prominent branded homeopathic products are Oscillococcinum, targeting influenza symptoms like fever, chills, headaches, and body aches; Stodal and Stodaline, developed for cough relief; Arnigel, for the localized adjunctive treatment of benign trauma without open wounds; Camilia, designed to alleviate teething problems in babies; and Sédatif PC, prescribed for anxiety, emotional distress, and minor sleep disorders. Additional homeopathic solutions include Coryzalia, for cold symptoms and rhinitis; Homéoptic, to soothe eye discomfort and irritation in all age groups; and Homéovox, for vocal disturbances. Beyond its core homeopathic range, Boiron also provides a selection of other health and wellness products. These encompass dietary supplements; the Dermoplasmine series (stick, balm, and mousse) for addressing dry lips and skin; Mag' Nuit, a formulation to assist with falling asleep; Arnitrosium, for joint pain; Castor Equi Boiron ointment, for cracked skin treatment; and Storinyl, a syrup to manage colds. Furthermore, the company offers herbal medicines, such as Canephron, which promotes diuresis and improved urinary elimination, alongside moisturizing baby milk and medical devices, including a range of COVID-19 self-tests and rapid antigenic tests. Boiron's products reach consumers through a comprehensive distribution network comprising dedicated centers, pharmacies, pharmacy chains, wholesalers, grocery stores, drugstores, health food stores, and various online retail channels.

Related entities

Parent
SOCIETE DE DEVELOPPEMENT ET DE VALORISATION-SODEVA
Subsidiaries
BOIRON LABORATORIES PRIVATE LIMITED

Key people

Anabelle Flory-Boiron
Non-Executive Chairman of the Board · since 2024
Thierry Boiron
Executive Director · since 2025
Pascal Houdayer
Chief Executive Officer, Executive Director · since 2025
Benjamin Boiron
Non-Executive Director · since 2023
Laurence Boiron
Non-Executive Director - Permanent Representative of Boiron Development · since 2023
Christine Boyer-Boiron
Non-Executive Director · since 2003
Stephanie Chesnot
Non-Executive Director · since 2010
Jean-francois Henaux
Non-Executive Director - Employees Representative · since 2021
Virginie Heurtaut
Non-Executive Director · since 2013
Evis Hursever
Non-Executive Director - Permanent Representative of Domino Fund 3 Holdco GP LLC · since 2023
Sylvain Mossaz
Non-Executive Director - Employees Representative · since 2020
Emmanuel Vigne
Non-Executive Director - Employee Representative · since 2024
Gregory Walter
Non-Executive Director - Representative of Shareholder Employees · since 2017
Non-Executive Independent Director · since 2021
Philippe Brown
Non-Executive Independent Director - Permanent Representative of FIDENTIS · since 2024
Jean- Marc Chalot
Non-Executive Independent Director · since 2022
IPO date
Mar 25, 1991
Employees
2,813
Domiciled in
FR
Incorporated in
FR
Headquarters & legal address
2 AVENUE DE L'OUEST LYONNAIS
MESSIMY 69510
FR

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT